Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate

  • Editas Medicine Inc EDIT has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder. 
  • Related Link: Editas Medicine Unveils Preclinical Data From New Gene Editing Technology.
  • Preliminary results include safety and efficacy data from the first two cohorts, the adult low-dose cohort (6x1011 vg/ml) and the adult mid-dose cohort (1.1x1012 vg/ml). 
  • Safety data were reported for all six subjects treated in the low dose (n=2) and mid-dose (n=4) cohorts. 
  • Most adverse events (AEs) were mild and primarily resulted from the surgical procedure and subretinal injection. There were no dose-limiting toxicities (DLTs). 
  • Investors are probably reacting to mild anterior chamber inflammation observed in patients and controlled with oral steroids. 
  • No Cas9-specific antibody or T-cell response was detected. 
  • To date, no treatment-related cataracts, edema, or retinal thinning have been observed.
  • Two of three subjects in the mid-dose cohort followed for up to six months showed efficacy signals suggesting productive editing and providing initial support for clinical benefits, including improvements in BCVA, FST, and/or mobility navigation.
  • In June, the Independent Data Monitoring Committee (IDMC) endorsed proceeding with the first pediatric cohort to review clinical safety data from the adult low-dose and mid-dose cohorts. 
  • Treatment in the adult high-dose cohort continues, and the pediatric mid-dose cohort is commencing.
  • Price Action: EDIT stock is down 20.50% at $41.71 during the market session on the last check Wednesday.

Posted In: BriefsGene EditingPhase 1 TrialPhase 2 Trialwhy it's movingBiotechNewsHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.